Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
Brainomix and Boehringer Ingelheim have expanded their partnership to accelerate diagnosis of progressive pulmonary fibrosis (PPF) using Brainomix's FDA‑cleared AI platform, e‑Lung. A retrospective study (REVISE‑PPF) showed e‑Lung could identify patients at risk up to 28 months before standard clinical diagnosis. The next phase, PROGRESS‑PPF, is a prospective, mixed‑methods trial across multiple U.S. sites to generate real‑world evidence of earlier detection and treatment initiation. Both companies aim to translate this earlier detection into improved patient outcomes.
Roche Gets Second European Approval for Alzheimer’s Test
Roche, in partnership with Eli Lilly, secured a CE mark for its second Elecsys blood test, the pTau217 assay, enabling sales across the European Economic Area. The new test can both confirm and exclude Alzheimer’s disease, expanding on the earlier pTau181...
Avalere Health Expands to Japan
Avalere Health announced the launch of a new office in Tokyo, marking its first dedicated presence in Japan. The office will provide end‑to‑end consulting for Japanese biopharmaceutical companies across oncology, diabetes, immunology and rare‑disease product lifecycles. Led by former McCann...
Zuckerberg Backed-Cellular Intelligence Acquires Novo Nordisk’s Parkinson’s Cell Therapy
Meta-backed Cellular Intelligence announced it has acquired Novo Nordisk's allogeneic stem cell therapy, STEM‑PD, for Parkinson's disease. The deal, terms undisclosed, gives Novo an equity stake and potential milestone payments and royalties. Cellular plans to apply its proprietary AI platform...
Makary’s Reported FDA Removal Could Be ‘Broad Positive’ for Biopharma
Industry sources report that President Donald Trump has approved a plan to remove FDA Commissioner Marty Makary, following the recent departure of CBER head Vinay Prasad. Makary’s tenure has been marked by calls for greater transparency but also criticism over...
Lilly and Caitlin Clark Reframe Progress with “Start How You Can”
Eli Lilly, together with Wieden+Kennedy Portland, launched the “Start How You Can” campaign featuring basketball phenom Caitlin Clark. The initiative reframes exercise as a form of preventive medicine, positioning health improvement over drug sales. Debuting alongside the WNBA season, the campaign...
Tariffs and Geopolitical Disruption Reshape Global Pharma Supply Chains
The U.S. administration has introduced tariffs on imported pharmaceuticals and their ingredients, reshaping trade rules and encouraging on‑shoring of drug manufacturing. The policy couples incentives with pricing agreements, prompting companies to invest tens of billions in expanding domestic production. Simultaneously,...
Zeno Strengthens Healthcare Communications in Europe
Zeno has appointed Cendrine Seror as Head of Health, Europe, expanding her role from Managing Director of Zeno France to overseeing the agency’s health and wellness practice across the continent. With more than 25 years in pharma, biotech and wellness...
Entrada Shares Sink After Duchenne Drug Falls Short of Expectations
Entrada Therapeutics reported that its experimental Duchenne drug ENTR-601-44 generated only a 2.36‑point increase in dystrophin, far below the 10‑11% rise analysts had modeled. The shortfall sent the company’s shares tumbling more than 50% in pre‑market trading. By contrast, Avidity...
Industry Veteran Mike Guarino Named CEO of EVERSANA INTOUCH
EVERSANA announced that industry veteran Mike Guarino will serve as CEO of its global health agency, EVERSANA INTOUCH. Guarino, formerly chief commercial officer at IPG Health and a longtime strategist at FCB Health, will steer strategy, operations and AI‑driven marketing...
Why the Pharma Industry Must Rethink Copay Solutions to Put Patients First
Affordability remains the biggest hurdle for U.S. patients seeking prescription therapies, as high‑deductible health plans and rising out‑of‑pocket costs delay initiation and erode adherence. Traditional manufacturer‑sponsored copay programs, built on static rules and linear adjudication, struggle to keep pace with...
Fingerpaint Group Unifies Operations and Strategy to Accelerate Integrated Growth
Fingerpaint Group appointed Stephanie Spicer as group managing director of operations and Nick Megjugorac as chief strategy officer, both reporting to President Mark Willmann. Spicer will extend her AI‑enabled operational framework across the firm’s three solution areas, while Megjugorac will...
Foundayo’s Liver Failure Blip Weighs Down Lilly Shares but Analysts Unconcerned
A single hepatic failure case linked to Eli Lilly’s new weight‑loss pill Foundayo appeared in the FDA’s adverse‑event database, prompting a brief sell‑off that pushed the stock down about 3% before rebounding to close up 0.48%. Lilly quickly investigated and...
Citrus Health Group Acquires The Medicine Group
Citrus Health Group, together with NaviMed Capital, has acquired The Medicine Group, a Doylestown‑based agency that specializes in scientific communication for CNS drug development. The acquisition bolsters Citrus' existing centers of expertise in oncology, rare diseases, and especially CNS disorders....
Axsome Gets FDA Approval for First Non-Antipsychotic Drug to Treat Agitation Associated with Alzheimer’s Dementia
The FDA has expanded the indication for Axsome Therapeutics’ Auvelity, approving it to treat agitation associated with Alzheimer’s disease dementia. This marks the first non‑antipsychotic medication cleared for this distressing symptom. Auvelity, originally approved in 2022 for major depressive disorder,...